Active Ingredient(s): Granisetron
FDA Approved: * September 12, 2008
Pharm Company: * STRAKAN INTL
Category: Cancer

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Sancuso Overview

Granisetron is a serotonin 5-HT3 receptor antagonist used as an antiemetic to treat nausea and vomiting following chemotherapy and radiotherapy. Its main effect is to reduce the activity of the vagus nerve, which is a nerve that activates the vomiting center in the medulla oblongata. It does not have much effect on vomiting due to motion sickness. This drug does not have any effect on dopamine receptors or muscarinic receptors. Granisetron was developed by chemists working at the British dr...

Read more Sancuso Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source:

Recent Sancuso Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

  • Film, Extended Release: 3.1mg/24hr
  • Injection: (1mg/ml) 1mg/1ml, (1mg/ml) 4mg/4ml, 0.1mg/ml, 0.1mg/ml (0.1mg/ml), 10mg/0.4ml, 1mg, 1mg/ml, 1mg/ml (1mg/ml), 3mg/ml, 4mg/4ml (1mg /ml), 4mg/4ml (1mg/ml)
  • Injection, Extended Release: 10mg/0.4ml (10mg/0.4ml)
  • Solution: 2mg/10ml
  • System: 3.1mg
  • Tablet: 1mg, 2mg
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Sancuso: (2 results)

Sorted by National Drug Code
  • 42747-726 Sancuso 3.1 mg/24h Transdermal Patch by Prostrakan, Inc.
  • 54868-5985 Sancuso 3.1 mg/24h Transdermal Patch by Physicians Total Care, Inc.

Other drugs which contain Granisetron or a similar ingredient: (3 results)